Phase 1 Myeloproliferative Neoplasms Clinical Trials
10 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–10 of 10 trials
Recruiting
Phase 1
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Primary myelofibrosis (PMF)Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Prelude Therapeutics100 enrolled5 locationsNCT07469891
Recruiting
Phase 1Phase 2
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)Essential Thrombocythemia, ET
Jubilant Therapeutics Inc.30 enrolled7 locationsNCT07612280
Recruiting
Phase 1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation218 enrolled49 locationsNCT07441694
Not Yet Recruiting
Phase 1
A Dose finding Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ZE74-0282 in Select JAK2 V617F Mutated Hematologic Disorders
Myeloproliferative Neoplasms (MPNs)
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)60 enrolled2 locationsACTRN12626000638336
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation186 enrolled30 locationsNCT06313593
Recruiting
Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation290 enrolled13 locationsNCT06034002
Recruiting
Phase 1
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation120 enrolled26 locationsNCT07008118
Recruiting
Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation225 enrolled29 locationsNCT05936359
Not Yet Recruiting
Phase 1
A Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZE74-0282 in Healthy Volunteers.
Myeloproliferative Neoplasms (MPN)
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)40 enrolled1 locationACTRN12626000214336
Recruiting
Phase 1
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Myeloproliferative Neoplasms
University of Chicago18 enrolled1 locationNCT06291987